FAQ: Vaginal Estrogen Tablets and Recurrent Stroke Risk in Postmenopausal Women

What is the main finding of this research?

The study found that using vaginal estrogen tablets was not associated with an increased risk of recurrent ischemic stroke in postmenopausal women who had previously experienced a stroke.

Why is this research significant for postmenopausal women with stroke history?

This is one of the first studies to analyze recurrent stroke risk specifically for this high-risk population using vaginal estrogen, providing crucial safety data where none previously existed.

How does vaginal estrogen differ from other hormone replacement therapies?

Unlike oral estrogen or transdermal formulations like creams and patches, vaginal estrogen tablets dissolve locally and are absorbed through the vaginal mucosa, resulting in a mild increase in estrogen in the bloodstream.

Who conducted this research and where was it published?

The study was led by Dr. Kimia Ghias Haddadan from Copenhagen University Hospital and published in Stroke, the peer-reviewed journal of the American Stroke Association.

What population was studied and how many participants were included?

The study examined more than 34,000 postmenopausal women aged 45 and older from a Danish national registry who had experienced a first ischemic stroke, excluding those who used vaginal estrogen before their first stroke.

Were there any differences in risk based on dosage or duration of use?

No increased risk of second stroke was found between high-dose or low-dose current use, and even women with higher cumulative use did not show higher risk compared to non-users.

How does this finding compare to previous research on vaginal estrogen?

While U.S. studies like the Women’s Health Initiative and Nurses’ Health Study showed no increased stroke risk with vaginal estrogen in healthy women, this study extends that reassurance to women with stroke history.

What common menopausal symptoms do vaginal estrogen tablets help manage?

Vaginal estrogen tablets help manage common menopausal symptoms such as vaginal dryness and discomfort during intercourse.

When was this research published and what was the study duration?

The research was published on August 21, 2025, and analyzed data over a 10-year study period from the Danish registry.